The Songdo Biocluster and the CDMO "Super-Plant" Model
In 2026, the city of Songdo, Incheon, has become the world's highest-capacity biomanufacturing site. Samsung Biologics has successfully operationalized dedicated Cell and Gene Therapy (CGT) tracks within its massive "Super-Plant" infrastructure.
By 2026, the South Korean CDMO market is growing at a CAGR of 25%, significantly outpacing the global average. This growth is driven by the industry's shift toward viral vector production (AAV and Lentivirus) and mRNA manufacturing. Major players like SK Bioscience and Celltrion have also diversified their portfolios, moving beyond vaccines and biosimilars into next-generation gene-modified cell therapies, positioning South Korea as a primary alternative to North American and European manufacturing hubs.